Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody

Blood

Volumn 99, Issue 4, 2002, Pages 1230-1236

  Li, Zhong Q ^a,b,c   Liu, Weiyi ^a,b,c   Park, Kwang S ^a,b,c   Sachais, Brue S ^a,b,c   Arepally, Gowthani M ^a,b,c   Cines, Douglas B ^a,b,c   Poncz, Mortimer ^a,b,c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Korea University College of Medicine   (South Korea)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYSTEINE; EPITOPE; HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KKO; PROLINE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CHIMERA; COMPLEX FORMATION; CRYSTAL STRUCTURE; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0037082459     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.4.1230     Document Type: Article

References (54)

1. Heparin-associated thrombocytopenia
2. Heparin-induced thrombocytopenia: Towards consensus
3. Heparin-induced thrombocytopenia: Pathogenesis and treatment
4. Arterial embolism occurring during systemic heparin therapy
5. Heparin: A cause of arterial emboli?
6. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
7. Antibodies from patients with heparin-induced thrombacytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cell
8. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
9. Heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
10. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia
11. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
12. Heparin-induced thrombocytopenia: Laboratory studies
13. Insights into heparin-induced thrombocytopenia
14. Immune endothelial-cell injury in heparin-associated thrombocytopenia
15. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia
16. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8
17. Platelet-derived CXC chemokines: Old players in new games
18. Human platelet factor 4: Complete amino acid sequence
19. Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line
20. Three dimensional structure of bovine platelet factor 4 at 3.0 A resolution
21. Crystal structure of recombinant human platelet factor
22. The crystal structure of recombinant human neutrophil-activating peptide-2 (M6L) at 1.9A resolution
23. NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: A symmetric tetramer
24. Heparin binding to platelet factor 4. An NMR and site-directed mutagenesis study: Arginine residues are crucial for binding
25. A model of the platelet factor 4 complex with heparin
26. Defining an antigenic epitope on platelet factor 4 (PF4) associated with heparin-induced thrombocytopenia and thrombosis (HITT)
27. A murine monoclonal antibody that mimics heparin-induced thrombocytopenia (HIT) antibodies
28. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA
29. Expression of recombinant platelet factor 4: Initial studies of its biologic properties
30. SWISS-MODEL the Swiss-PdbViewer: An environment for comparative protein modeling
31. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
32. Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: Generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin
33. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery
34. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or lowmolecular-weight heparin
35. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: Platelet factor 4 complexes
36. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery
37. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid
38. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium
39. Impact of the patient population on the risk for heparin-induced thrombocytopenia
40. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia
41. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis
42. Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha: Induction of a partially folded state and implications for heparin-induced thrombocytopenia
43. The epitope specificity of heparin-induced thrombocytopenia
44. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: Platelet factor 4
45. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies
46. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia
47. Platelets of patients with peripheral arterial disease demonstrate a hypersensitive response to heparin
48. Characterization of the humoral immune response in heparin-induced thrombocytopenia
49. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
50. FcγRIIA H/R131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
51. Heparin-induced thrombocytopenia: New insights into the impact of the FcγRIIa-R-H131 polymorphism
52. Importance of the FcγRIIaArg/His131 polymorphism in heparin-induced thrombocytopenia diagnosis
53. Interaction of antithrombin III with bovine aortic segments: Role of heparin in binding and enhanced anticoagulant activity
54. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C: A potential mechanism for enhancing generation of activated protein C